Methods of Preparing T Cells for T Cell Therapy

Inactive Publication Date: 2017-05-18
KITE PHARMA INC +1
View PDF2 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method to measure the effect of AKTi on T cell activity. T cells are grown in different conditions and co-cultured with target cells that produce light. By measuring the intensity of the light, the researchers can determine if the T cells have recognized and killed the target cells. The results show that cells cultured in the presence of AKTi have greater cytotoxicity than cells cultured without it.

Problems solved by technology

However, it has proven difficult to predict whether a given T cell therapy will be effective in each patient.
As a result, the expected in vivo persistence of these cells can be limited, and positive effects initially observed can be undone over time as tumors rebound in the absence of transplanted T cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of Preparing T Cells for T Cell Therapy
  • Methods of Preparing T Cells for T Cell Therapy
  • Methods of Preparing T Cells for T Cell Therapy

Examples

Experimental program
Comparison scheme
Effect test

embodiments

[0176]E1. A method for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation, and / or wherein the resulting T cells exhibit improved T cell function relative to a T cell function of a T cell cultured in the absence of an AKT inhibitor.

[0177]E2. A method for improving T cell function in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit an improved T cell function relative to a T cell function of a T cell cultured in the absence of an AKT inhibitor.

[0178]E3. The method of E1...

example 1

[0240]Donor T cells were cultured in the presence of IL-2, IL-7, IL-15, and / or an AKT inhibitor for 10 days, at equal plating concentrations. The T cell phenotype of the cultured T cells was determined for CD4+ T cells and CD8+ T cells cultured for 7 and 14 days in (i) IL-2 alone as compared to IL-7 and IL-15 and (ii) cultured in IL-7 and IL-15 as compared to IL-7, IL-15, and an AKT inhibitor (FIG. 1A-FIG. 1F). A trend towards more juvenile T-cells was observed when cells were grown in the presence of IL-7 and IL-15. In particular, a significantly higher (p=0.03, n=6) percent of naïve and Tcm cells CD4+ was observed in IL-7 / IL-15 treated cells as compared to IL-2 treated cells (FIG. 1A), whereas no difference was observed in the percent of more mature effector T cells (FIG. 1B). This effect was not maintained after long term culture in the CD4+ compartment (data now shown). A similar effect was observed in the CD8+ compartment, with a significantly higher (p=0.03, n=6) percent of na...

example 2

[0243]The effects of AKTi inhibitors on cell expansion were investigated under various conditions. First, the effect of AKTi culture conditions on various sources of donor cells was evaluated as follows. Apheresis products from four healthy donors were processed using high density centrifugation to obtain peripheral blood mononuclear cells (PBMCs) (FIGS. 4A-4D). Cells from four donors were counted and stimulated using OKT3 (a monoclonal antibody to CD3), and cultured in the presence of IL-2 (circles); IL-2 and AKTi (squares); IL-7 and IL-15 (triangles); or IL-7, IL-15, and AKTi (inverted triangles) for 7 to 10 days (FIGS. 4A-4D). Cell expansion was observed for each donor cell line under each culture condition, and AKTi had no negative impact on cell expansion (FIGS. 4A-4D).

[0244]Next, class I TCR transduced (HPV-E6) PBMCs were evaluated. Apheresis products from three healthy donors were again processed using high density centrifugation to obtain PBMC, counted, and stimulated using ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Login to view more

Abstract

Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application Ser. No. 62 / 244,036 filed Oct. 20, 2015, which is incorporated herein by reference in its entirety.STATEMENT OF GOVERNMENT INTEREST[0002]This invention was created in the performance of a Cooperative Research and Development Agreement with the National Cancer Institute (NCI), an Agency of the Department of Health and Human Services. The Government of the United States has certain rights in this invention.FIELD OF THE INVENTION[0003]This invention relates to methods of preparing one or more T cells for a T cell therapy. In particular, the invention relates to a method of improving the efficacy of a T cell therapy by contacting one or more T cells with an AKT inhibitor (“AKTi”) and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15).BACKGROUND[0004]Human cancers are by their nature comprised of normal cells that have undergone a genetic or ep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/17A61K39/00C07K14/725C12N5/0783
CPCA61K35/17C12N5/0638C12N5/0636A61K39/0011C07K14/7051C12N2501/727A61K2039/5156C12N2501/2315A61K2039/5158A61K2039/572C12N2501/2302C12N2506/11C12N2501/2307A61P35/00A61P35/02C12N2510/00A61K39/4632A61K39/464838A61K39/464486A61K39/4611C12N15/86A61K39/001157A61K39/001189A61K39/001161A61K39/001112A61K39/001168A61K39/001153A61K39/00117A61K39/001113A61K39/001124A61K39/001192A61K39/001106A61K39/001195A61K39/001171A61K39/001182A61K39/00118A61K39/001193A61K39/001104A61K39/001119A61K39/001156A61K39/001166A61K39/001181A61K39/001186A61K39/001191A61K39/001194A61K39/001197A61K39/001162A61K39/001176A61K39/001188A61K39/001109A61K39/001184
Inventor PEREZ, ARIANNESABATINO, MARIANNAROSENBERG, STEVEN A.RESTIFO, NICHOLAS P.
Owner KITE PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap